Are you a new member? Sign up now
Login area
| Sign up
close
ABRILADA - 40mg - 2
| ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L04AB04 | BioTech | Adalimumab - 40mg | 11325 | 147822/1 | ABRILADA | 40mg | 2 | Injectable solution | SC | Food & Drug Corporation FDC | Catalent Indiana, LLC | USA | 40,259,574 L.L | 10.71 | E1 | Pfizer Europe MA EEIG | Belgium | 12/12/20 | 0 |
Drugs With Same Ingredients
| ATC | B/G | Ingredients | code | Registration Nb | Name | Dosage | Presentation | Form | Route | Agent | Laboratory | Country | Price | Pharmacist Margin | Stratum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| L04AB04 | BioTech | Adalimumab - 40mg/0.4ml | 9597 | 135418/1 | HUMIRA | 40mg/0.4ml | 2 x 0.4ml | Injectable solution | SC | Interpharma S.A.L. | Vetter Pharma- Fertigung GmbH & Co KG | Germany | 33,860,031 L.L | 10.71 | E1 | Abbvie Deutschland GmbH & Co KG | Germany | 12/12/20 | 0 |
| L04AB04 | BioTech | Adalimumab - 40mg/0.8ml | 10085 | 125519/1 | CINNORA | 40mg/0.8ml | 2 | Injectable solution | SC | Lebiran SARL | Cinnagen Co | Iran | 14,817,734 L.L | 19.35 | D | Cinnagen Co | Iran | 12/12/20 | 0 |
| L04AB04 | BioTech | Adalimumab - 40mg | 11326 | 147922/1 | ABRILADA | 40mg | 2 | Injectable solution | SC | Food & Drug Corporation FDC | Catalent Indiana, LLC | USA | 40,259,574 L.L | 10.71 | E1 | Pfizer Europe MA EEIG | Belgium | 12/12/20 | 0 |
| L04AB04 | BioTech | Adalimumab - 40mg | 11585 | 106523/1 | ADALIREL | 40mg | 1x0.8ml | Injectable solution | SC | Levant Pulse SARL | Reliance Life Sciences pvt Ltd | India | 15,102,158 L.L | 19.35 | D | Reliance Life Sciences pvt Ltd | India | 12/12/20 | 0 |
| L04AB04 | BioTech | Adalimumab - 40mg | 9748 | 41219/1 | HYRIMOZ | 40mg | 2 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Sandoz GmbH, (Schaftenau) | Austria | 26,053,947 L.L | 10.71 | E1 | Sandoz GmbH, Kundl | Austria | 12/12/20 | 0 |
| L04AB04 | BioTech | Adalimumab - 40mg | 9749 | 41119/1 | HYRIMOZ | 40mg | 2 | Injectable solution | SC | Khalil Fattal & Fils S.A.L. | Sandoz GmbH, (Schaftenau) | Austria | 26,053,947 L.L | 10.71 | E1 | Sandoz GmbH, Kundl | Austria | 12/12/20 | 0 |
| L04AB04 | BioTech | Adalimumab - 40mg/0.4ml | 9597/388 | 135418/1 | HUMIRA | 40mg/0.4ml | 2 x 0.4ml | Injectable solution | SC | Interpharma S.A.L. | Vetter Pharma- Fertigung GmbH & Co KG | Germany | L.L | 10.71 | E1 | Abbvie Deutschland GmbH & Co KG | Germany | 05/02/20 |
Sitemap
© Copyrights reserved to Ministry of Public Health 2024